OPKO Health, Inc announced that it has acquired exclusive worldwide rights from Teva Pharmaceuticals Industries Ltd (TEVA) to Teva's proprietary formulation of budesonide for the treatment of various inflammatory and allergic conditions of the eye.
The details can be read here.
No comments:
Post a Comment